Alpha Tau Medical (DRTS) Total Non-Current Liabilities (2020 - 2026)
Alpha Tau Medical (DRTS) posted Total Non-Current Liabilities of $29.0 million for Q1 2026, up 60.55% sequentially from $18.0 million in Q4 2025, and up 95.28% YoY from $14.8 million in Q1 2025.
Analysis
Alpha Tau Medical (DRTS) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
Alpha Tau Medical has reported Total Non-Current Liabilities for 7 years, with the latest figure at $29.0 million in Q1 2026.
- Quarterly Total Non-Current Liabilities rose 95.28% year-over-year to $29.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29.0 million (up 95.28% YoY) and the FY2025 annual result came in at $18.0 million, up 21.42% from the prior year.
- Total Non-Current Liabilities rose to $29.0 million in Q1 2026 per DRTS's latest filing, from $18.0 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $29.0 million in Q1 2026 and troughed at $8.1 million in Q1 2022.
- A 5-year average of $15.2 million and a median of $15.0 million in 2024 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities soared 196.19% in 2022, then declined 9.41% in 2025.
- Over 5 years, Total Non-Current Liabilities stood at $10.2 million in 2022, then soared by 55.71% to $15.8 million in 2023, then dropped by 6.0% to $14.9 million in 2024, then gained by 21.42% to $18.0 million in 2025, then jumped by 60.55% to $29.0 million in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $29.0 million, $18.0 million, and $18.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 3.92 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 1.53 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.88 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 9.32 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Alpha Tau Medical | 1.21 Bn | 1.11 Bn | - | 80.56 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 80.56 Mn |
| Mar 31, 2026 | 28.97 Mn |
| Dec 31, 2025 | 18.05 Mn |
| Sep 30, 2025 | 17.97 Mn |
| Jun 30, 2025 | 16.18 Mn |
| Mar 31, 2025 | 14.84 Mn |
| Dec 31, 2024 | 14.86 Mn |
| Sep 30, 2024 | 14.98 Mn |
| Jun 30, 2024 | 15.58 Mn |
| Mar 31, 2024 | 16.38 Mn |
| Dec 31, 2023 | 15.81 Mn |
| Sep 30, 2023 | 10.65 Mn |
| Jun 30, 2023 | 13.23 Mn |
| Mar 31, 2023 | 11.55 Mn |
| Dec 31, 2022 | 10.15 Mn |
| Sep 30, 2022 | 3.35 Mn |
| Jun 30, 2022 | 2.76 Mn |
| Mar 31, 2022 | 6.30 Mn |
| Dec 31, 2021 | 4.41 Mn |
| Mar 31, 2021 | -8.46 Mn |